|
C22ORF28 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.44010034400333E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.72339994999982E-09 |
| Normal-vs-Stage2 |
2.362800E-04 |
| Normal-vs-Stage3 |
1.09079999999206E-06 |
| Normal-vs-Stage4 |
4.78830000094632E-08 |
| Stage1-vs-Stage2 |
8.391800E-01 |
| Stage1-vs-Stage3 |
6.504800E-01 |
| Stage1-vs-Stage4 |
1.013800E-01 |
| Stage2-vs-Stage3 |
6.263000E-01 |
| Stage2-vs-Stage4 |
2.969200E-01 |
| Stage3-vs-Stage4 |
6.074000E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.45320000056427E-09 |
| Normal-vs-AfricanAmerican |
1.724910E-03 |
| Normal-vs-Asian |
2.569800E-04 |
| Caucasian-vs-AfricanAmerican |
6.048200E-01 |
| Caucasian-vs-Asian |
7.736200E-01 |
| AfricanAmerican-vs-Asian |
8.131400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.87480000413132E-08 |
| Normal-vs-Female |
1.17639997743169E-09 |
| Male-vs-Female |
4.287400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.22090000331809E-08 |
| Normal-vs-Age(41-60Yrs) |
6.86419998618959E-09 |
| Normal-vs-Age(61-80Yrs) |
1.42280000003936E-07 |
| Normal-vs-Age(81-100Yrs) |
2.103000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.901600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.710000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.314400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.710400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.277800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.003200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.968390E-01 |
| Classical-VS-Follicular |
1.77103999999817E-05 |
| Classical-VS-Other |
3.606800E-01 |
| Classical-VS-Normal |
1.59740000005293E-07 |
| Tall-VS-Follicular |
4.03030000000193E-05 |
| Tall-VS-Other |
2.093800E-01 |
| Tall-VS-Normal |
2.965500E-02 |
| Follicular-VS-Other |
8.227200E-01 |
| Follicular-VS-Normal |
8.27560242555592E-13 |
| Other-VS-Normal |
7.186200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.72339961482749E-10 |
| Normal-vs-N1 |
4.62469999962245E-07 |
| N0-vs-N1 |
2.236800E-01 |
|
|
